Disorder "Acute Myeloid Leukemia"
Found 13 records
Disorder information
Disorder name:
Acute Myeloid Leukemia
Disoder ID:
OMIM entry:
Synonyms:
AML - acute Myeloid Leukemia,Leukemia, Myelocytic, acute,acute myeloblastic leukemia,acute myelogenous leukemia
Definition:
A form of leukemia characterized by overproduction of an early myeloid cell
Modifier statisitcs
Record:
13
Gene:
7
Variant:
9
Reference:
3
Effect type:
Expressivity(13)
Modifier effect:
Risk factor(13)
| Modifier gene | Variant | Effect type | Modifier effect | Evidence | Effect | PubMed ID |
|---|---|---|---|---|---|---|
| MAP2K4 | MAP2K4:c.-1304G>T | Expressivity | Risk factor | Adjusted OR=0.67; 95% CI: 0.51-0.87 | The functional -1304G>T variant may contribute to the risk of AML by enhancing the transcriptional activity of MKK4.more | more |
| IDH2 | IDH2:c.124A>T(p.Arg172Trp) | Expressivity | Risk factor | From review article | Somatic mutations in epigenetic modifiers, including IDH1, IDH2, TET2, DNAMT3A, ASXL1, MLL and EZH2 are enriched in patients with acute myeloid leukemia (AML), especially those with intermediate-risk cytogeneticsmore | more |
| IDH2:c.125G>T(p.Arg42Met) | Expressivity | Risk factor | From review article | Somatic mutations in epigenetic modifiers, including IDH1, IDH2, TET2, DNAMT3A, ASXL1, MLL and EZH2 are enriched in patients with acute myeloid leukemia (AML), especially those with intermediate-risk cytogeneticsmore | more | |
| IDH2:c.263G>T(p.Arg140Leu) | Expressivity | Risk factor | From review article | Somatic mutations in epigenetic modifiers, including IDH1, IDH2, TET2, DNAMT3A, ASXL1, MLL and EZH2 are enriched in patients with acute myeloid leukemia (AML), especially those with intermediate-risk cytogeneticsmore | more | |
| IDH2:c.263G>T(p.Arg140Leu) | Expressivity | Risk factor | From review article | Somatic mutations in epigenetic modifiers, including IDH1, IDH2, TET2, DNAMT3A, ASXL1, MLL and EZH2 are enriched in patients with acute myeloid leukemia (AML), especially those with intermediate-risk cytogeneticsmore | more | |
| IDH1 | IDH1:c.394C>G(p.Arg132Gly) | Expressivity | Risk factor | From review article | Somatic mutations in epigenetic modifiers, including IDH1, IDH2, TET2, DNAMT3A, ASXL1, MLL and EZH2 are enriched in patients with acute myeloid leukemia (AML), especially those with intermediate-risk cytogeneticsmore | more |
| IDH1:c.394C>G(p.Arg132Gly) | Expressivity | Risk factor | From review article | Somatic mutations in epigenetic modifiers, including IDH1, IDH2, TET2, DNAMT3A, ASXL1, MLL and EZH2 are enriched in patients with acute myeloid leukemia (AML), especially those with intermediate-risk cytogeneticsmore | more | |
| IDH1:c.394C>G(p.Arg132Gly) | Expressivity | Risk factor | From review article | Somatic mutations in epigenetic modifiers, including IDH1, IDH2, TET2, DNAMT3A, ASXL1, MLL and EZH2 are enriched in patients with acute myeloid leukemia (AML), especially those with intermediate-risk cytogeneticsmore | more | |
| IDH1:c.394C>G(p.Arg132Gly) | Expressivity | Risk factor | From review article | Somatic mutations in epigenetic modifiers, including IDH1, IDH2, TET2, DNAMT3A, ASXL1, MLL and EZH2 are enriched in patients with acute myeloid leukemia (AML), especially those with intermediate-risk cytogeneticsmore | more | |
| GSTM1 | GSTM1 | Expressivity | Risk factor | P=0 | We found that the ABCC3 C-211T polymorphism and GSTM1 null genotype have adverse prognostic significance in AML.more | more |